Stay updated on Optune in Melanoma Brain Mets + Immune Checkpoint Inhibitors Clinical Trial
Sign up to get notified when there's something new on the Optune in Melanoma Brain Mets + Immune Checkpoint Inhibitors Clinical Trial page.

Latest updates to the Optune in Melanoma Brain Mets + Immune Checkpoint Inhibitors Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe record presents details of a terminated phase II study evaluating Optune TTFields with nivolumab and ipilimumab for melanoma with brain metastases, including its eligibility criteria, treatment plan, outcomes, and results.SummaryDifference49%

- Check15 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0 while the page continued to display a 403 error instead of the study record.SummaryDifference0.2%

- Check22 days agoChange DetectedA banner announces NIH’s transition from the term “Artificial Intelligence” to “Super Intelligence” across its content and links to transition updates and FAQs.SummaryDifference1%

- Check28 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2; the page continues to display a 403 error.SummaryDifference0.2%

- Check35 days agoChange DetectedThe ClinicalTrials.gov footer now identifies the site revision as v3.7.1 instead of v3.7.0.SummaryDifference0.2%

- Check56 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study record and navigation with an access-denied screen. This indicates a restriction or system issue that prevents viewing the trial details.SummaryDifference18%

Stay in the know with updates to Optune in Melanoma Brain Mets + Immune Checkpoint Inhibitors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Optune in Melanoma Brain Mets + Immune Checkpoint Inhibitors Clinical Trial page.